Daewoong Pharmaceutical

069620 · KOSPI · South Korea

Public Market Listing

069620KOSPI

KOSPI primary exchange listing

Live quotes, historical charts, and market capitalization for Daewoong Pharmaceutical are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(7 total)
7Total Assets
0Approved
4Phase 3 / Filed
3Phase 1–2 / Early
6Diseases
Quick filter:
Showing 7 of 7 assets
Target & Modality
Phase 3
Undisclosed / early pipelineSmall molecule
HypertensionAtherosclerotic Cardiovascular Disease
Phase 3
SGLT2Small molecule
Type 2 DiabetesChronic Kidney Disease
Gemigliptin(Zemiglo)
Phase 3
DPP-4Small molecule
Type 2 Diabetes
Olmesartan/rosuvastatin (DWJ1276)(Olostar)No recent activity
Phase 3
Angiotensin II receptor / HMG-CoA reductaseSmall molecule
Hypertension
Phase 1
Nurr1 (NR4A2, nuclear orphan receptor)Small molecule
Parkinson's Disease
Phase 1
GLP-1 receptorPeptide
Obesity
OLOMAXNo recent activity
Preclinical / Unstaged
Angiotensin II receptor / Calcium channel / HMG-CoA reductaseSmall molecule
HypertensionAtherosclerotic Cardiovascular Disease

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
November 2027 (1)
Enavogliflozin · EnvloPhase 3T2DM (Type 2 Diabetes Mellitus)
Est. primary completion 2027-11 · NCT07619833 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Annual history (2 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$1.1B$155M——report ↗
View 1 more year
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$1.0B———report ↗